Journal: Frontiers in Veterinary Science

Article Title: Detection of bimodal survivin expressions in canine cancer types by flow cytometry compared to immunohistochemistry

doi: 10.3389/fvets.2025.1552415

Figure Lengend Snippet: Analysis of survivin expression sites by IHC and WB. (A) Images of HE staining and survivin expression via IHC in canine melanoma cell lines (CMM2, CMeC, and LMeC) are shown. (B) Images of HE staining and survivin expression via IHC in murine cell lines (p815, CT26, and B16F10) are shown. (C) The cytosol and total survivin expression patterns via WB are indicated. (D) The expression levels of total survivin (blue bar) and cytosolic survivin (orange bar) corrected on the basis of β-actin expression are shown via density of plot analysis via ImageJ software.

Article Snippet: A total of six cell lines were used: canine malignant melanoma lines [CMM2, CMeC2, LMeC; provided by Dr. Takayuki Nakagawa, Department of Veterinary Surgery, University of Tokyo; ( )], the murine malignant melanoma line B16F10, the murine mast cell tumor line p815, and the murine colon cancer line CT26 (distributed for a fee by the JCRB Cell Bank).

Techniques: Expressing, Staining, Software

Journal: Clinical Cancer Research

Article Title: Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade

doi: 10.1158/1078-0432.ccr-18-1932

Figure Lengend Snippet: Figure 2. Intratumoral injection of JX leads to systemic and cancer-specific immune responses. Mice were s.c. injected with Renca tumor cells in the right flank and with Renca or CT26 tumors in the left flank. Arrows indicated intratumoral JX treatment. A, Growth curves of JX-injected Renca tumor and noninjected Renca tumor. B, Representative images and comparisons of CD8þ T cells in the JX-injected and noninjected tumors. C, Growth curve of JX-injected Renca tumor and noninjected CT26 tumor. D, Representative images and comparisons of CD8þ T cells in the JX-injected and noninjected tumors. Unless otherwise denoted, n ¼ 5 for each group. Values are mean SD. , P < 0.05 versus control. ns, not significant. Two-tailed Student t test was used. Scale bars, 50 mm.

Article Snippet: The Renca murine renal cancer cell line and the CT26 murine colon cancer cell line were obtained from the ATCC (#CRL-2947) and Korean Cell LineBank (#80009).

Techniques: Injection, Control, Two Tailed Test

Journal: Clinical Cancer Research

Article Title: Tumor Microenvironment Remodeling by Intratumoral Oncolytic Vaccinia Virus Enhances the Efficacy of Immune-Checkpoint Blockade

doi: 10.1158/1078-0432.ccr-18-1932

Figure Lengend Snippet: Figure 5. The triple combination of JX and aPD-1 and aCTLA-4 induces profound tumor regression and provides a long-term survival benefit in kidney cancer. Mice were s.c. implanted with Renca tumors and treated with or without JX and immune-checkpoint blockades for PD-1 and CTLA-4 on the indicated days (arrows). A, Comparisons of tumor growth. Mean and individual tumor growth curves over time. Pooled data from two experiments with 8 animals per group. , P < 0.05 versus control; #, P < 0.05 versus JX; $, P < 0.05 versus aPD-1þ aCTLA-4. ns, not significant. Two-tailed Student t test was used. B, Waterfall plot showing the maximal percent changes from baseline in tumor size. C, Comparison of tumor size after injection of Renca or CT26 tumor cells into mice with complete tumor regression or into na€ve mice. D, Kaplan–Meier plot for overall survival. n ¼ 8–11 for each group. Log-rank test was used.

Article Snippet: The Renca murine renal cancer cell line and the CT26 murine colon cancer cell line were obtained from the ATCC (#CRL-2947) and Korean Cell LineBank (#80009).

Techniques: Control, Two Tailed Test, Comparison, Injection

Journal: eLife

Article Title: A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

doi: 10.7554/eLife.71156

Figure Lengend Snippet: ( A, B ) Differential gene expression profile (DESeq) in CT26 versus medullary thymic epithelial cell (mTEC) ( A ) and CT26 versus healthy Balb/c colon ( B ) is depicted as volcano plot of -log 10 of p-adj-values versus log 2 ratio (fold change). The source proteins of MHC-I ligands from our dataset are marked in red, and the differential expression is considered significant for a fold change of 1.5 and a padj-value of 0.05 (red square). ( C ) Scatter plot comparing the fold change of the source proteins found statistically overexpressed in both DESeq analysis and the average binding affinity score for both H2K d and H2D d allotypes. The values were considered significant for >-log 10 0.5 H_average ranks and the third quartile of average fold change (red marked). ( D, E ) The peptides were stratified based on their binding affinity expressed as -log 10 and on the weighted score to prioritize similarity between more central amino acids in the peptide ( D ) or on the percentage of similarity to viral peptides ( E ). Binding affinity <50 nM and weighted score and similarity >0.8 were considered as the threshold to select tumor peptides similar to viral epitopes.

Article Snippet: Murine colon carcinoma CT26 cell line was purchased from ATCC (ATTC CRL-2639) and cultured in RPMI-1640 supplemented with 1% GlutaMAX (Gibco, Invitrogen, Carlsbad, CA), 10% heat-inactivated fetal bovine serum (Gibco), and 1% penicillin-streptomycin (10,000 U/mL) (Gibco).

Techniques: Gene Expression, Quantitative Proteomics, Binding Assay

Journal: eLife

Article Title: A novel immunopeptidomic-based pipeline for the generation of personalized oncolytic cancer vaccines

doi: 10.7554/eLife.71156

Figure Lengend Snippet: (A) A schematic representation of the animal experiment setting is depicted. Immunocompetent Balb/c mice were subcutaneously injected with the syngeneic tumor model CT26 in the left (0.6 × 10 6 cells) and right flanks (1 × 10 6 ). PeptiCRAd was intratumorally administrated four times, 2 days apart. (B) The CT26 tumor growth was followed until the end of the experiment, and the tumor size is presented as the mean ± SEM. Statistically significant difference was assessed with two-way ANOVA (*p<0.05; ***p<0.001; ****p<0.0001; ns, nonsignificant).

Article Snippet: Murine colon carcinoma CT26 cell line was purchased from ATCC (ATTC CRL-2639) and cultured in RPMI-1640 supplemented with 1% GlutaMAX (Gibco, Invitrogen, Carlsbad, CA), 10% heat-inactivated fetal bovine serum (Gibco), and 1% penicillin-streptomycin (10,000 U/mL) (Gibco).

Techniques: Injection